Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?

NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients

  • August 12, 2026

  • 12 min

Share

  • 1

    NurExone Biologic is developing exosome-based therapeutics to enhance precision in delivering therapies to damaged tissues.

  • 2

    ExoPTEN, NurExone's lead candidate, targets PTEN to support nerve repair in conditions like spinal cord and optic nerve injuries.

  • 3

    Exosomes serve as natural delivery vehicles that respond to distress signals, facilitating therapeutic cargo transport to damaged areas.

  • 4

    Manufacturing exosome-based therapies faces challenges in consistency due to variability in biological systems and production conditions.

  • 5

    The acellular approach of using exosomes may allow for easier development of off-the-shelf products with broader applicability.

Original Source(s)

Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?

  • August 12, 2026

Related Content

Can SGLT2 Inhibitors Affect Dementia?

A target trial emulation using Veterans Affairs electronic health records examined neuropsychiatric outcomes associated with SGLT2 inhibitor use.

Persistent hypersensitivity after repeat concussion is associated with chronic cognitive dysfunction

Longitudinal assessment of intraocular pressure in the 5xFAD mouse model of Alzheimer's disease